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Abstract Real-time quaking-induced conversion (RT-QuIC)
allows the amplification of miniscule amounts of scrapie prion
protein (PrPSc). Recent studies applied the RT-QuIC methodol-
ogy to cerebrospinal fluid (CSF) for diagnosing human prion
diseases. However, to date, there has not been a formal multi-
centre assessment of the reproducibility, validity and stability of
RT-QuIC in this context, an indispensable step for establish-
ment as a diagnostic test in clinical practice. In the present
study, we analysed CSF from 110 prion disease patients and
400 control patients using the RT-QuIC method under various
conditions. In addition, “blinded” ring trials between different
participating sites were performed to estimate reproducibility.
Using the previously established cut-off of 10,000 relative fluo-
rescence units (rfu), we obtained a sensitivity of 85 % and a
specificity of 99 %. The multi-centre inter-laboratory reproduc-
ibility of RT-QuIC revealed a Fleiss’ kappa value of 0.83 (95%
CI: 0.40–1.00) indicating an almost perfect agreement. More-
over, we investigated the impact of short-term CSF storage at
different temperatures, long-term storage, repeated freezing and
thawing cycles and the contamination of CSFwith blood on the
RT-QuIC seeding response. Our data indicated that the PrPSc
seed in CSF is stable to any type of storage condition but
sensitive to contaminations with blood (>1250 erythrocytes/
μL), which results in a false negative RT-QuIC response. Fresh
blood-contaminated samples (3 days) can be rescued by remov-
al of erythrocytes. The present study underlines the reproduc-
ibility and high stability of RT-QuIC across various CSF stor-
age conditions with a remarkable sensitivity and specificity,
suggesting RT-QuIC as an innovative and robust diagnostic
method.
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Introduction
Transmissible spongiform encephalopathies or prion diseases
are characterized by the aggregation and accumulation of
misfolded scrapie prion protein (PrPSc) in brain tissue. They
can occur spontaneously (sporadic) but also be due to familial
and iatrogenic causes. Sporadic Creutzfeldt-Jakob disease
(sCJD) is the most common prion disease in human, followed
by genetic CJD (gCJD) and iatrogenic CJD (iCJD). Different
molecular sCJD subtypes, which show unique clinicopatho-
logical phenotypes and transmission characteristics [1] and
depend on the codon 129 genotype of the prion protein gene
(PRNP) as well as the type of PrPSc, have been reported [2, 3].
The adaptation of in vitro amplification systems for the
detection of PrPSc in human cerebrospinal fluid (CSF) was
an innovation for the pre-mortem diagnosis. RT-QuIC analysis
uses recombinant prion protein (recPrP) as a substrate to am-
plify very small amounts of PrPSc seed in human CSF to
detectable levels. Time course of conversion can bemonitored
in real-time by a fluorescent dye using a fluorescent reader.
Four previous studies demonstrated the diagnostic potential of
RT-QuIC through amplification of PrPSc from human CSF,
derived from sCJD and gCJD patients [4–7].
However, despite these initial reports, establishing RT-
QuIC as a routine diagnostic test in clinical practice requires
a comprehensive validation and standardization. To date, there
is a lack of studies dealing with inter-laboratory reproducibil-
ity and standardization, assessment of short- and long-term
stability and contamination of CSF samples with potential
inhibitory blood cells of the RT-QuIC seeding response in
human CSF of CJD patients. All of these parameters may lead
to an artificial decrease or increase of PrP seeding activity in
CSF and to false positive or negative results.
The aim of the present study was to further analyse the
applicability of RT-QuIC for routine diagnostic purposes.
Analysis of 110 CSF samples from prion disease patients
and 400 from a control panel consisting of 200 retrospectively
tested patients (diagnoses including Alzheimer’s disease
[AD], Parkinson’s disease [PD], inflammatory [IF] and other
non-prion diseases) and 200 prospectively randomly selected
patients was undertaken to obtain diagnostic data more
aligned to a routine clinical setting. Also, two ring trials were
performed to generate data about the reproducibility of the RT-
QuIC assay. Finally, the influence of different CSF storage
conditions (long- and short-term storage or repeated freezing
and thawing cycles) and the influence of blood contamination
on the RT-QuIC seeding response were examined.
Materials and Methods
Patients
CSF samples were collected through routine activities of the
German National Prion Disease Surveillance Center associat-
ed with the University Medical Center Göttingen. Samples
were derived from 110 prion disease patients, consisting of
64 sCJD, 39 gCJD (33 E200K, 6 V210I mutation carriers)
and 7 FFI (D178N mutation), as well as 400 control patients.
Initial data on the cohort have been published elsewhere [7].
The data were used to calculate the sensitivity and specificity.
All prion disease cases were neuropathologically confirmed.
The 200 retrospectively tested control patients represent
those with either a clinically or pathologically defined alter-
native diagnosis (92 female, 108 male; aged 16–87 years;
mean age 64.1±0.9 years at notification). This control group
consisted of AD patients (rapid progressive and classical
forms), patients with depression, Dementia with Lewy bodies,
PD, psychosis, bipolar disorder, multiple sclerosis, epilepsy,
schizophrenia, inflammatory CNS disease and others. The
200 prospective samples were enrolled from the Neurochem-
istry Laboratory at the Department of Neurology in the frame-
work of quality assurance and were tested blinded for clinical
and personal data. Gender- and age-dependent effects on the
RT-QuIC seeding response were excluded before [7].
CSF Samples
CSF samples were stored at −80 °C prior to analysis.
Haemorrhagic CSF samples were excluded from the study.
Ethical Statement
The study was conformed to the Code of Ethics of the World
Medical Association and informed consent was given by all
study participants or their legal next of kin with the study
being approved by the local ethics committee in Goettingen
(No. 24/8/12). All samples were analysed blinded for at least
personal data.
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RT-QuIC Analysis
The RT-QuIC was performed as described previously [7].
Briefly, 85 μL of reaction buffer were seeded with 15 μL of
freshly thawed and neat CSF to a final volume of 100 μL, with
each CSF sample generally run in triplicate. Prepared plates
were sealed (VWR, Hannover, Germany) and incubated in a
plate reader (FLUOStar OPTIMA, BMG Labtech, Ortenberg,
Germany) at 42 °C for 80 h with intermittent shaking cycles,
consisting of 1 min double orbital shaking at 600 rpm follow-
ed by a 1-min break. Beta-sheet formation kinetic was deter-
mined by measuring the thioflavin T (ThT) fluorescent signal
(450 nm excitation and 480 nm emission) every 30 min in
relative fluorescence units (rfu). When we obtained more than
50 % positive replicates (signal ≥10,000 rfu after 80 h), the
sample was considered as positive. Controls were considered
as negative when more than 50 % of the replicates revealed a
RT-QuIC response after 80 h below 10,000 rfu.
Expression and Purification of Recombinant Sheep-Hamster
PrP
All RT-QuIC experiments were performed using the chimeric
recPrP composed of the Syrian hamster residues 14 to 128
followed by sheep residues 141 to 234 of the R154 Q171 poly-
morphic haplotype as described before [7, 8]. The recPrP was
prepared and its functionality was verified according to the
method described by Wilham et al. [9].
Study Design
The present study was performed in three stages in order to
determine the reproducibility, stability and validity of RT-
QuIC for use as a diagnostic test for human prion diseases:
1. To investigate the reproducibility of the RT-QuIC assay,
we conducted two ring trial studies between different lab-
oratories. Fifty-four CSF samples obtained from sCJD
patients and 32 non-prion disease controls were examined
in two laboratories (UMG, Thermo Fisher Scientific). In a
second ring trial, one sCJD and five controls were inves-
tigated in four laboratories (UMG, Ilsong Institute of Life
Science, Nagasaki University Graduate School of Bio-
medical Sciences, Western General Hospital, and Univer-
sity of Melbourne).
2. To calculate specificity, sensitivity and predictive values
of the RT-QuIC assay, we analysed CSF samples from
110 prion disease patients, as well as from 400 control
patients.
3. To determine the stability of RT-QuIC, sCJD CSF sam-
ples (n=12) and control samples (n=6) were incubated
under short- and long-term storage conditions.
4. To assess the impact of blood contamination of CSF sam-
ples on the RT-QuIC response, we spiked CSF from sCJD
(n=6–8) and control samples (n=6–8) with defined
amounts of blood cells from control patients.
5. To investigate the impact of transportation on blood-
contaminated samples, we spiked CSF from sCJD (n=8)
and control samples (n=8) with a defined amount of
blood cells from control patients and incubated the CSF
samples for 0, 1, 3 and 8 days at room temperature.
Statistical Analysis
In the first part of this study, inter-rater reliability within ring
trials was calculated using the Fleiss’ kappa for multiple
readers. A Fleiss’ kappa value of >0.60 was defined as sub-
stantial agreement, Fleiss’ kappa >0.80 as almost perfect
agreement between raters.
To test the diagnostic validity, we established a training
dataset consisting of 28 CJD patients and nine controls, which
were not part of the present study. A Receiver operating char-
acteristic (ROC) analysis was performed on this dataset, and
the best cut-off value was estimated to be 10,000 rfu based on
the Youden index. We thereby confirmed the analysis of
McGuire et al. [4] in an independent dataset and applied the
cut-off value of 10,000 rfu to this study.
For the analysis of the stability of RT-QuIC, a two-step
approach was performed. First, positivity rates were calculated
(defining a seeding efficiency of ≥10,000 rfu within 80 h as
positive) and were compared between groups using ANOVAs.
Agreement levels and Fleiss’ kappas were calculated in order
to investigate the stability of positivity under different circum-
stances. Then, measurements of seeding efficiency were calcu-
lated for each individual sample defined by relative area under
the curve (rel. AUC) and maximal ThTsignal (maximum), and
groups were compared using paired and unpaired t tests as
appropriate. For graphical illustration, time series plots are pre-
sented at each step of the analysis, displaying means of seeding
activity for each point in time (each measurement) in the re-
spective groups. Thus, these illustrations show aggregated data
for each point in time, but information about means of AUCs
or individual maximums cannot be read out of these plots [7].
Sensitivity, specificity and predictive values of RT-QuIC
were calculated for the entire dataset as well as for distinct
subgroups. All analyses were conducted using Stata 12 soft-
ware (StataCorp, College Town, US) and R 2.15.3 software.
Analysis of CSF by ELISA for 14-3-3
Levels of 14-3-3 protein in CSF were determined by using the
CircuLex 14-3-3 Gamma ELISA Kit (BIOZOL Diagnostica
Vertrieb GmbH, Eching, Germany) according to a previously
established protocol [7].
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Determination of Total Tau Level
CSF levels of total tau protein were measured using a com-
Innogenetics). For the determination of tau levels, we follow-
ed the manufacturer’s instructions.
Results
Reliability of RT-QuIC Assay in Comparison to 14-3-3
and Tau Proteins
To investigate the reproducibility of PrPSc amplification via RT-
QuIC assay, we initiated two ring trial studies and included com-
parison to other biomarker proteins (tau and 14-3-3). Results of
inter-laboratory agreement were indicated as Fleiss’ kappa, which
was calculated in a first ring trial with two partners as 0.75 (95 %
CI: 0.40–1.00) revealing a substantial agreement, comparable to
14-3-3 and tau proteins (Supplement 1). A second ring trial with
four raters showed an almost perfect agreement (Fleiss’ kappa=
0.83 (95 % CI: 0.40–1.00)), proving high reliability and repro-
ducibility of the RT-QuIC assay (Supplement 1).
Determination of the Specificity and Sensitivity of RT-QuIC
Assay
Using a cut-off at 10,000 rfu/80 h (defined by Youden
index[10]), an overall sensitivity of 85 % for all prion diseases
and a specificity of 99 % could be achieved (Fig. 1a–c). Ge-
netic CJD cases showed a sensitivity of 100 %, while analysis
of sCJD and FFI CSF samples revealed a sensitivity of 80 and
57 %, respectively (Fig. 1c). The control cohort consisted of
Fig. 1 Analysis of the sensitivity and specificity of the RT-QuIC assay.
RT-QuIC response was measured in rfu over a period of 80 h. a RT-QuIC
signalling response was evaluated as a diagnostic test by using receiver
operating characteristic (ROC) curves. The ROC curve of the training
dataset is shown suggesting a cut-off at 10,000 rfu. b Prion diseases
exhibited a median RT-QuIC signal of 35,000 rfu, while controls
remained under 10,000 rfu. c Considering >50 % positive RT-QuIC
replicates as positive for prion disease, we obtained a specificity of
99 % and an averaged sensitivity of 85 %. d Two hundred CSF
samples, retrospectively tested by RT-QuIC, are summarized
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mercially available ELISA kit (INNOTEST® hTAU Ag,
200 patients with different diagnoses, e.g. AD, PD, IF etc.
(Fig. 1d) and 200 prospectively tested patients.
However, we obtained two false positive results with a RT-
QuIC response higher than 10,000 rfu in the control samples
(Supplement 2). CSF sample 1 was from a patient originally
clinically diagnosed as AD, while for sample 2, the diagnosis
was still outstanding at the time of RT-QuIC analysis. Sample
1 showed no abnormalities with respect to 14-3-3 and total tau
protein levels, while the second patient exhibited elevated tau
and 14-3-3 levels, as well as a positive MRI, in keeping with
prion disease. For patient 1, autopsy was not available and the
patient has been lost to follow-up.
Stability of the RT-QuIC Seeding Response with Long-
and Short-Term CSF Storage Conditions
CSF samples derived from 12 sCJD and six control patients
were stored in polypropylene tubes at room temperature or 4 °C
for up to 8 days. To estimate the impact of long-term storage on
the stability of RT-QuIC seeding response, we analysed sCJD
(n=12) and control (n=6) samples, which were stored for 2–3,
5–6 or 8–9 years in a −80 °C freezer. Additionally, we subjected
12 sCJD and six control CSF samples to up to 16 repeated
freezing and thawing cycles.
We calculated for each indicated condition the percent of
positive replicates per sample defined as a seeding response of
more than 10,000 rfu (cut-off) in 80 h (3/3=100%, 2/3=66%,
1/3=33 % and 0/3=0 %), which is important for CJD diag-
nostic. Our data indicated that the PrPSc seed in the RT-QuIC
reaction remained stable under the analysed short- and long-
term storage conditions and was resistant to up to 16 repeated
freezing and thawing cycles (Fig. 2a–d). Under short-term
storage conditions, the temperature had no significant influ-
ence on the number of positive replicates.
Subsequently, we analysed the RT-QuIC seeding efficiencies
as a second parameter, which describes the intensity of the RT-
QuIC signal, under the indicated storage conditions. We defined
seeding efficiency as a combination of the following two param-
eters of interest: rel. AUC and the signal maximum of RT-QuIC
response (maximum). Again, we observed that the seeding effi-
ciency of PrPSc was not significantly influenced, neither under
short-term nor under long-term storage conditions or after re-
peated freezing and thawing cycles of CSF samples (Fig. 3a–d).
Control samples without prion disease showed negative
RT-QuIC responses (<10,000 rfu) under these conditions (data
not shown).
Influence of Blood Contamination on RT-QuIC Seeding
Response in CSF
Since erythrocytes and platelets in human blood contamina-
tion of CSF may influence PrPSc seeding activity in the RT-
QuIC assay, we spiked CSF derived from sCJD patients (n=
6–8) and non-CJD controls (n=6–8) with different amounts of
Fig. 2 Effect of various storage
conditions on the RT-QuIC signal
response. RT-QuIC reactions
seeded with CSF from sCJD
patients were analysed under
short-term storage conditions
(8 days) at room temperature (RT)
and 4 °C (a, b), after 16 repeated
freezing and thawing cycles (c)
and after long-term storage (up to
9 years) (d). There was no
significant trend for decreasing
positivity rates over time when a
storing at room temperature (p=
0.337), b storing at 4 °C (p=
0.713) or c after 16 freezing and
thawing cycles (p=0.537) and d
over several years of storage at
−80 °C. Numbers of positive
replicates were calculated for
each sample in percent. Standard
deviation of the mean from n=12
patients per group was indicated
by error bars. For comparison
between groups, we used
ANOVAs
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sonicated red blood cells from control donors (78, 313, 1250,
5000 or 10,000 erythrocytes/μL).
Our results indicated that an erythrocyte concentration
higher than 1250 cells/μL showed a false-negative RT-QuIC
response. Blood contaminations significantly influenced the
number of positive replicates (Fig. 4a) as well as the signal
intensity of the RT-QuIC response (Fig. 4c).
In contrast, erythrocyte concentrations below 1250 cells/
μL are tolerable for diagnostics because they did not show
any significant impact on the number of positive replicates
and the intensity of the RT-QuIC signal (Fig. 4a, c). CSF from
non-prion controls, spiked with blood always revealed a neg-
ative RT-QuIC seeding response (data not shown).
Subsequently, we simulated the impact of transportation on
blood contaminated samples by spiking CSF samples from
sCJD (n=8) and control samples (n=8) with a defined amount
of blood cells (5000 cells/μL) from control patients. After 0, 1,
3 and 8 days, we centrifuged the samples to remove the blood
cells. The haemolysis and release of inhibitory proteins, which
influence the number of positive replicates and the intensity of
the RT-QuIC signal significantly, started after 3 days resulting
in a false-negative RT-QuIC seeding response in sCJD pa-
tients (Fig. 4b, d). For comparison, we used non-spiked CSF
from sCJD patients as a reference.
Discussion
The development of in vitro conversion assays, such as pro-
tein misfolding cyclic amplification (PMCA), enhanced quak-
ing induced conversion (eQuIC) or RT-QuIC, exploit the self-
propagating replication of the abnormally folded PrPSc to am-
plify miniscule amounts of PrPSc to a detectable level. Al-
though these assays initially employed brain material, four
recent studies demonstrated the capacity of RT-QuIC to repli-
cate PrPSc from human CSF [4–7].
Fig. 3 Time course of prion seeding activity in the CSF of sCJD patients
after defined storage conditions. RT-QuIC reactions seeded with CSF
from sCJD patients were analysed under short-term storage conditions
(8 days) at room temperature (RT) and 4 °C (a, b) after long-term storage
(up to 9 years) (c) and after 16 repeated freezing and thawing cycles (d).
The PrPSc seeding efficiency was not significantly changed under these
conditions. Graphically displayed are means of all positive replicates per
group at each point in time. The absolute values for rel. AUC and signal
maximum were shown for each group, and the p values were calculated
for each comparative analysis. p values were obtained using paired or
unpaired t tests for comparisons of maximum values and rel. AUCs
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The use of RT-QuIC in routine CSF diagnostics for prion
diseases requires standardization of sample treatments, defini-
tions of cut-off values by analyzing a high number of samples
and assessments of reproducibility and resistance of the RT-
QuIC response to short- and long-term storage conditions;
until now, only scarce information on these topics is available
in the literature.
Reproducibility of the RT-QuIC Assay Between Different
Study Sites
To evaluate the inter-laboratory reproducibility of the RT-
QuIC assay, we initiated ring trials between different
laboratories. A first RT-QuIC ring trial between two different
partners using a high number of samples (54 sCJD and 32
controls) indicated substantial agreement between raters
(Fleiss’ kappa=0.75 (95 % CI: 0.40–1.00)).
Even though the inter-laboratory agreement was relatively
high, we intended to establish optimal conditions and standard
operating procedures for the RT-QuIC method. The assay pre-
cision depends on various factors including (1) inter-
laboratory variations in staff, protocols and substrates; (2)
sensitivity of the assay to different CSF sample storage and
shipping temperatures and (3) different fluorescent readers.
By minimizing such variations, we achieved in a second ring
trial an almost perfect agreement (Fleiss’ kappa=0.83 (95 %
Fig. 4 Influence of blood contamination on the RT-QuIC seeding
response. CSF from sCJD patients (n=6–8) was spiked with defined
amounts of sonicated red blood cells. a The number of positive
replicates was calculated and revealed that sCJD CSF samples spiked
with more than 1250 cells/μL showed a false-negative RT-QuIC
response. b CSF from sCJD (n=8) patients was spiked with 5000 cells/
μL and incubated at room temperature without sonication for 8 days
showing that a significant inhibition via haemolysis of the RT-QuIC
response started after 3 days. c, d Graphically displayed are means of
all positive replicates per group at each point in time. Absolute values
for rel. AUC and signal maximum were shown for each group, and the
p values were calculated for each comparative analysis. All p values
<0.05 were considered as significant
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CI: 0.40–1.00)) showing a high reproducibility of the RT-
QuIC assay with improved standardization and supporting
the potential of the method for routine diagnostic purposes.
Sensitivity, Specificity and Predictive Values of the RT-QUIC
Assay
We analysed CSF samples from a patient cohort consisting of
110 patients with prion disease (sCJD, gCJD and FFI) and 400
controls. When setting the cut-off at 10,000 rfu, we obtained a
specificity of 99 % and a sensitivity of 85 % for all prion
diseases. Among different prion diseases, the sensitivity var-
ied from 100 % for gCJD, 80 % for sCJD and 57 % for FFI
cases. Our data are in line with two previous studies, which
reported a specificity of almost 100 % and a sensitivity be-
tween 80 and 90 % [4, 5]. For gCJD patients, Sano et al.
reported sensitivities of RT-QUIC as follows: FFI (100 %),
gCJD E200K (87 %) and gCJD V203I (100 %) [6]. Discrep-
ancies for FFI patients may be explained by sampling errors
because of the low number of specimens tested (7 versus 22
per group) and methodological differences [6, 7].
Short- and Long-Term Stability of RT-QuIC Seeding
Response in CSF
A general problem of biomarker-based diagnostics is the sen-
sitivity of biomarker proteins to storage and shipment condi-
tions. During shipment, CSF is subjected for a defined period
of time (between 1 and 8 days) to different temperatures,
which are between 20 and 25 °C. After arrival, CSF is usually
stored at 4 °C before analysis. Samples, which are used for
research, may undergo numerous cycles of freezing and
thawing or will be stored for years at −80 °C.
For simulation of these conditions, we explored the effect
of short-term storage (up to 8 days at room temperature or at
4 °C), long-term storage (up to 8–9 years at −80 °C), as well as
the influence of 16 repeated freezing and thawing cycles on
the RT-QuIC seeding response. Our data demonstrated that the
PrPSc seed in CSF of sCJD patients resisted the variations
posed with across the analysed conditions, and we did not
obtain any loss of sensitivity or specificity or in relation to
the intensity of the RT-QuIC responses.
Compared to other biomarker proteins such as tau or
Aβ42, which become degraded in particular under higher
temperatures during storage [11–13], the proven stability of
RT-QuIC assay is a clear advantage with respect to diagnostic
purposes.
Influence of Blood Contamination on the RT-QuIC Response
in CSF of sCJD Patients
Contamination with blood cells, such as erythrocytes, may
influence the RT-QuIC response. In routine diagnostic
laboratory practice, between 5 and 10 % of the CSF samples
are contaminated with blood cells during the lumbar puncture.
Therefore, there is a need to define clear guidelines for pre-
analytical sample handling. Our data revealed an artificial in-
hibition of the PrPSc seeding activity which resulted in a false-
negative RT-QuIC response in prion disease patients. Our
findings may explain the variable sensitivity of the RT-QuIC
assay (between 80 and 90 %) among different laboratories [4,
5]. The obtained data indicated that a blood cell contamination
higher than 1250 cells/μL may inhibit the RT-QuIC reaction,
when all cells were completely haemolysed by sonication. A
contamination with <1250 cells/μL can be considered as un-
problematic. In CSF samples (not older than 3 days after the
lumbar puncture), a centrifugation step before freezing is rec-
ommended to remove blood cells. After 3 days, haemolysis of
blood cells was increased to such an amount that no reliable
results could be obtained. Therefore, it is strongly suggested to
exclude these samples from further diagnostic analysis.
In conclusion, our data emphasize that RT-QuIC analysis of
CSF is a robust and very useful tool for prion diagnosis and
should become part of the clinical workup in rapidly progres-
sive dementia cases.
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